Corteva
CTVA
$12.88
0Corteva is a pure-play agricultural inputs company formed in 2019 from the DowDuPont spin-off, developing and selling seeds and crop protection products to farmers globally, with roughly half of revenue generated in North America. It is a market leader in seed genetics and chemistry, competing alongside Bayer, Syngenta, and FMC in an industry defined by R&D intensity, patent cliffs, and weather- and commodity-cycle exposure. The dominant investor narrative right now is the planned late-2026 separation of the seeds business into a standalone company named Vylor, leaving Corteva as a pure-play crop protection operator — a transaction management frames as a value-unlocking catalyst. That thesis is being stress-tested by a violent share-price collapse, soft top-line trends, and a JPMorgan upgrade in early October arguing the post-spinoff entity is undervalued, while investors await Q3 results for confirmation.…
CTVA
Corteva
$12.88
Related headlines
Investment Opinion: Should I buy CTVA Today?
Rating: Hold. The core thesis is that CTVA is a deeply discounted agricultural inputs pure-play with a strong balance sheet (D/E 0.107) and a potential value-unlocking spin-off catalyst, but stagnant revenue (-1.19% YoY), weak trailing profitability (6.29% net margin, 4.53% ROE), and a broken chart (-78.89% 1Y) warrant caution until stabilization is proven. The analyst consensus is 'buy' with a mean rating of 1.67 and an average target of $22.05 (+71% upside), but the wide target range ($13.65-$75.00) signals low conviction.
Supporting evidence: (1) Forward PE of 10.12x is a meaningful discount to mid-teens peer multiples; (2) PS of 2.62x is near the bottom of the stock's multi-year range (6.04x-17.53x); (3) Q2 2026 gross margin of 54.35% and operating margin of 30.02% are stable YoY; (4) EV/EBITDA of 14.21x is moderate for the sector; (5) the balance sheet is strong with interest coverage of ~40.7x. However, FCF yield is thin at ~1.4%, and the 41.89x trailing PE versus 10.12x forward PE implies an earnings quadrupling that may not materialize.
Key risks: (1) Spin-off execution could destroy value if the retained crop protection business is valued at a discount; (2) revenue stagnation could persist if commodity prices remain weak; (3) the stock could retest the $9.08 52-week low (-29.5%). The rating would upgrade to Buy if the stock stabilizes above $14.62 (52-week high) and Q3 results show revenue growth or margin expansion. It would downgrade to Sell if revenue declines accelerate below -5% or if the spin-off is delayed/canceled. Valuation verdict: the stock appears undervalued relative to its own history and peers on forward metrics, but the discount is justified by execution risk and stagnant growth — hence Hold, not Buy.
Sign up to view all
CTVA 12-Month Price Forecast
CTVA presents a high-risk, potentially high-reward situation. The stock is deeply discounted on forward earnings (10.12x) and sales (2.62x), with a strong balance sheet and a clear catalyst (Vylor spin-off). However, stagnant revenue, weak trailing profitability, and a catastrophic price collapse create significant uncertainty. The analyst consensus is bullish but lacks conviction given the wide target range. I would upgrade to bullish if the stock stabilizes above $14.62 and Q3 results show revenue growth or margin expansion. I would downgrade to bearish if the stock breaks below $9.08 or if the spin-off is delayed.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Corteva's 12-month outlook, with a consensus price target around $17.24 and implied upside of +33.9% versus the current price.
Average Target
$17.24
0 analysts
Implied Upside
+33.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$14 - $20
Analyst target range
Twelve analysts cover the stock with a consensus recommendation of "buy" and a mean rating of 1.67 on a scale where 1 is a strong buy, implying a bullish tilt despite the collapse. The average target price of $22.05 implies roughly +71% upside from the current $12.88, but that figure is heavily skewed by stale pre-spin targets and should be treated with caution. Recent institutional actions are mixed rather than uniformly positive: Argus reiterated Buy on 2026-09-18, BMO Capital and RBC Capital both reiterated Outperform on 2026-09-16, while Citigroup, UBS, and JP Morgan all maintained Neutral through August and September, and the early-October JPMorgan upgrade cited in news coverage highlights post-spinoff undervaluation. The target range is extraordinarily wide, from a low of $13.65 — essentially the current price, implying no upside — to a high of $75.00, a spread of more than 5x that signals very low conviction and unresolved disagreement about what the post-spin entity is worth. The high target likely assumes successful separation, multiple re-rating of the pure-play crop protection business, and recovery in agricultural commodity prices, while the low target effectively prices in continued margin pressure, competitive share loss in crop protection, and no re-rating benefit from the spin. Consensus 2027 EPS of $0.774 (range $0.736 to $0.991) against estimated revenue of $8.556 billion implies a forward multiple near 16.6x at the current price, which is more demanding than the 10.12x forward PE figure and suggests the headline valuation data may not be fully consistent with the post-spin earnings base — a discrepancy investors should resolve before acting on either number.
Bulls vs Bears: CTVA Investment Factors
The bear case currently has stronger evidence: the stock is in a catastrophic downtrend (-78.89% 1Y, -86.83% max drawdown), revenue is stagnant (-1.19% YoY), and trailing profitability is weak (6.29% net margin, 4.53% ROE). However, the bull case rests on a genuine catalyst — the late-2026 Vylor spin-off — and a deeply discounted forward valuation (10.12x forward PE) with a strong balance sheet (D/E 0.107). The single most important tension is whether the post-spin crop protection business can re-rate or whether the spin merely crystallizes value destruction; resolution hinges on Q3 results and spin execution details.
Bullish
- Deep discount to forward earnings: At $12.88, CTVA trades at just 10.12x forward EPS versus a mid-teens typical multiple for large-cap seed and chemistry peers. The 2.62x PS and 2.36x EV/Sales are near the bottom of the stock's own multi-year range (PS ranged from 6.04x in Q2 2024 to 17.53x in Q3 2025), suggesting trough sentiment.
- Strong balance sheet supports spin: Debt-to-equity of 0.107 and a current ratio of 1.43 provide ample financial flexibility to execute the late-2026 Vylor spin-off. Interest coverage of roughly 40.7x in Q2 2026 (operating income $1.915B vs. interest expense $47M) leaves little refinancing risk.
- Analyst consensus still bullish: Twelve analysts rate the stock a 'buy' with a mean rating of 1.67 (1=strong buy) and an average target of $22.05, implying +71% upside. Recent actions include Argus reiterating Buy on 2026-09-18 and BMO/RBC reiterating Outperform on 2026-09-16, plus a JPMorgan upgrade in early October citing post-spinoff undervaluation.
- Stable peak-season margins: Q2 2026 gross margin was 54.35% and operating margin 30.02%, essentially flat versus Q2 2025's 54.58% gross margin. Net income of $1.161B on $6.379B revenue demonstrates the core business remains highly profitable at seasonal peak despite flat sales.
Bearish
- Catastrophic price collapse: The stock is down 78.89% over one year and 80.99% YTD, with a max drawdown of -86.83%. The 84% single-session gap from $77.65 on 2026-09-30 to $12.57 on 2026-10-01 signals a corporate-action-driven repricing, but the subsequent drift between $11.92 and $14.45 shows the market is still price-discovering the new entity.
- Stagnant revenue and weak profitability: Q2 2026 revenue fell 1.19% YoY to $6.379B, and trailing net margin is only 6.29% with ROE of 4.53%. Off-season quarters produce large losses (Q3 2025 net loss $320M, Q4 2025 net loss $552M), making earnings highly seasonal and volatile.
- Thin free cash flow yield: Trailing free cash flow of $629M against a $45.6B market cap implies a FCF yield of just ~1.4%. Cash generation is back-end loaded and working-capital intensive: Q1 2026 operating cash flow was -$2.891B on a $4.056B working-capital build, while Q4 2025 generated $4.375B.
- Valuation discrepancy clouds outlook: The 41.89x trailing PE versus 10.12x forward PE implies the market expects earnings to roughly quadruple, which is inconsistent with consensus 2027 EPS of $0.774 (implying ~16.6x at current price). This discrepancy suggests the headline forward PE may not reflect the post-spin earnings base.
CTVA Technical Analysis
The prevailing trend is a catastrophic downtrend, with the stock down 78.89% over the past year and 80.99% year-to-date, a decline that dwarfs the S&P 500's +15.53% one-year gain and produces a relative strength reading of -94.42 versus the index. At $12.88, the shares sit at roughly 68% of the 52-week range bounded by a $9.08 low and $14.62 high, but that positioning is misleading: the range itself has collapsed, and the price is only modestly above the low after a vertical decline. The maximum drawdown of -86.83% confirms this is a broken chart rather than a routine correction, and the proximity to the 52-week low signals a falling-knife profile rather than a value entry point until stabilization is proven. Momentum is uniformly negative and accelerating in severity: -84.10% over one month, -85.25% over three months, and -83.97% over six months, with the one-month and three-month figures nearly identical, indicating a single discontinuous repricing event rather than a gradual bleed. The daily series shows the break clearly — the stock traded near $77.65 on 2026-09-30 and closed at $12.57 on 2026-10-01, a roughly 84% single-session gap that is consistent with a spin-off adjustment or corporate action rather than ordinary selling, and the subsequent drift between $11.92 and $14.45 suggests the market is still price-discovering the new entity. Relative strength of -85.32 over one month versus a +1.22% S&P gain underscores that no short-term mean-reversion bid has emerged, and with volume of 15.7 million shares and a short ratio of 4.46, positioning remains contentious. Key levels are the $14.62 52-week high as resistance and the $9.08 52-week low as the critical support floor; a reclaim of $14.62 would mark the first evidence of a durable base, while a break below $9.08 would signal the repricing is not yet complete. Beta is not available in the provided data, but the -86.83% drawdown and the 84% single-day gap imply extreme realized volatility far beyond market-level risk, which argues for materially smaller position sizing and wider stops than a typical Basic Materials holding.
Beta
—
—
Max Drawdown
-86.8%
Largest decline past year
52-Week Range
$9-$15
Price range past year
Annual Return
-78.9%
Cumulative gain past year
| Period | CTVA Return | S&P 500 |
|---|---|---|
| 1m | -84.1% | +0.2% |
| 3m | -85.2% | +2.9% |
| 6m | -84.0% | +8.4% |
| 1y | -78.9% | +14.9% |
| ytd | -81.0% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTVA Fundamental Analysis
Revenue is essentially flat to slightly declining: Q2 2026 revenue of $6.379 billion fell 1.19% year-over-year from $6.456 billion in Q2 2025, and the sequential pattern shows Q1 2026 at $4.905 billion versus $4.417 billion a year earlier, so the first half is roughly in line with the prior year rather than deteriorating sharply. Segment data for the latest period shows Seed at $4.532 billion and Crop Protection at $1.847 billion, confirming seeds remain the dominant revenue and profit engine — which is precisely the business being separated into Vylor, leaving the retained Corteva more dependent on the smaller, more cyclical and more competitive crop protection line. The investment case therefore hinges less on current growth, which is stagnant, and more on whether the sum of the two parts is worth more than the whole. Profitability is highly seasonal but healthy at the peak: Q2 2026 net income was $1.161 billion on a 54.35% gross margin and 30.02% operating margin, versus $1.314 billion and a 54.58% gross margin in Q2 2025, so margins are essentially stable year-over-year at the seasonal high. The trailing picture is distorted by losses in the off-season quarters — Q3 2025 net loss of $320 million and Q4 2025 net loss of $552 million — which drag trailing net margin to 6.29% and trailing ROE to just 4.53%, well below what a 47.29% trailing gross margin would normally support. The balance sheet is the strongest part of the story: debt-to-equity of 0.107 is very low, the current ratio of 1.43 is adequate, and interest coverage of roughly 40.7x in Q2 2026 leaves ample room, while trailing free cash flow of $629 million against a $45.6 billion market cap implies a thin FCF yield of about 1.4%. Cash generation is heavily back-end loaded and working-capital driven — Q1 2026 operating cash flow was -$2.891 billion on a $4.056 billion working-capital build, while Q4 2025 generated $4.375 billion — so the company funds itself internally across the full year but carries meaningful intra-year liquidity swings.
Quarterly Revenue
$6.4B
2026-06
Revenue YoY Growth
-1.2%
YoY Comparison
Gross Margin
54.4%
Latest Quarter
Free Cash Flow
$629000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTVA Overvalued?
Because trailing net income is positive ($1.161 billion in Q2 2026 alone, with a positive trailing figure implied by the 41.89x trailing PE), the PE ratio is the appropriate primary metric, and the gap between the 41.89x trailing and 10.12x forward PE is enormous — it implies the market expects earnings to roughly quadruple, which is consistent with a post-spin adjusted earnings base rather than genuine fundamental acceleration. The 2.62x PS and 2.36x EV/Sales look far less demanding than the trailing PE, and the 14.21x EV/EBITDA is moderate for an agricultural inputs business, suggesting the trailing earnings multiple is distorted by one-off items and seasonality rather than reflecting true earning power. Against an agricultural inputs peer set where large-cap chemistry and seed companies typically trade in the mid-teens on forward earnings, the 10.12x forward PE represents a meaningful discount, and the 1.89x PEG and 1.89x price-to-book are not stretched — the discount appears justified by stagnant revenue (-1.19% YoY), a 6.29% net margin, and the execution risk of splitting the company. Historical ratios show the stock's own PE band has been wildly unstable — 12.24x in Q2 2026, 19.56x in Q1 2026, negative in the loss-making Q3 and Q4 2025, and 9.65x in Q2 2025 — while PS has ranged from 6.04x in Q2 2024 to 17.53x in Q3 2025. At 2.62x sales the stock is now near the bottom of its own multi-year PS range, which historically has coincided with trough sentiment rather than peak optimism; the question is whether this is a genuine value opportunity created by the spin-off dislocation or a signal of fundamental deterioration in the retained crop protection business.
PE
41.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. Revenue is stagnant (-1.19% YoY in Q2 2026) and trailing net margin is only 6.29% with ROE of 4.53%, well below what a 47.29% gross margin would normally support due to large off-season losses (Q3 2025 net loss $320M, Q4 2025 net loss $552M). Free cash flow yield is thin at ~1.4% ($629M TTM FCF vs. $45.6B market cap), and cash generation is highly seasonal with Q1 2026 operating cash flow of -$2.891B on a $4.056B working-capital build. The spin-off adds execution risk: separating seeds (Vylor) from crop protection leaves the retained Corteva more dependent on the smaller, more cyclical crop protection segment ($1.847B of Q2 2026 revenue vs. $4.532B for seeds).
Market and competitive risks are elevated. The stock trades at 10.12x forward PE, a discount to peers, but this may be justified by stagnant growth and spin execution risk. The 84% single-session gap on 2026-10-01 indicates a corporate-action-driven repricing, and the subsequent drift between $11.92 and $14.45 shows the market is still price-discovering the new entity. Relative strength is deeply negative (-94.42 vs. S&P 500 over one year), and the stock has shown no mean-reversion bid. Competitive pressures from Bayer, Syngenta, and FMC in crop protection, plus weather and commodity-cycle exposure, add cyclical risk. Beta is not provided, but the -86.83% drawdown implies extreme realized volatility far beyond market-level risk.
Worst-case scenario: If the spin-off is poorly received, crop protection margins compress further, and agricultural commodity prices remain depressed, the stock could retest its 52-week low of $9.08, implying a -29.5% decline from $12.88. A break below $9.08 would signal the repricing is not complete and could trigger further selling toward the analyst low target of $13.65 (which is actually above current price, but stale) or lower. Given the -86.83% max drawdown, an investor could lose 30-50% from current levels in an adverse scenario, especially if Q3 results disappoint and the spin timeline slips.
FAQ
The biggest risk is spin-off execution: separating seeds (Vylor) from crop protection could leave the retained Corteva with a less profitable, more cyclical business, and any delay or unfavorable terms could trigger further selling. Second, revenue stagnation (-1.19% YoY) could persist if agricultural commodity prices remain depressed, pressuring margins. Third, the stock is in a severe downtrend (-78.89% 1Y, -86.83% max drawdown) with no technical support until $9.08, implying up to -29.5% downside. Fourth, competitive pressure from Bayer, Syngenta, and FMC in crop protection could erode market share. Finally, thin FCF yield (~1.4%) and seasonal cash burn (Q1 2026 operating cash flow -$2.891B) limit financial flexibility.
Our 12-month forecast has three scenarios: Bull (25% probability, $22-$30) assumes a successful spin-off, commodity recovery, and re-rating toward peer multiples; Base (50%, $13-$18) assumes the spin proceeds but skepticism lingers, with revenue stabilizing and margins holding; Bear (25%, $9-$12) assumes spin delays, margin compression, and a retest of the $9.08 low. The base case is most likely, implying modest upside from $12.88. The key assumption is that the spin-off completes on schedule and the retained business trades at a discount to peers but not at distressed levels. Analyst average target of $22.05 aligns with the bull case, but we view it as optimistic given current fundamentals.
CTVA appears undervalued on forward metrics. The forward PE of 10.12x is well below the mid-teens typical for large-cap agricultural peers, and the 2.62x PS is near the bottom of its multi-year range (6.04x-17.53x). EV/EBITDA of 14.21x is moderate. However, the 41.89x trailing PE is distorted by seasonality and one-off items, and the gap between trailing and forward PE implies the market expects earnings to roughly quadruple — a tall order given stagnant revenue. The discount is justified by execution risk around the spin-off and weak growth, but if the spin succeeds, the stock could re-rate toward peer multiples, implying significant upside. The market is pricing in skepticism, not optimism.
CTVA is a high-risk, high-reward special situation. The stock trades at 10.12x forward PE and 2.62x PS, deep discounts to peers and its own history, with a strong balance sheet (D/E 0.107) and a clear catalyst in the late-2026 Vylor spin-off. However, revenue is stagnant (-1.19% YoY), trailing net margin is only 6.29%, and the stock has collapsed 78.89% over the past year. The analyst consensus is 'buy' with a $22.05 average target (+71% upside), but the wide range ($13.65-$75.00) signals low conviction. It could be a good buy for contrarian investors with a high risk tolerance and a 12-24 month horizon, but only after the stock stabilizes above $14.62 or Q3 results confirm the thesis. The biggest downside risk is a retest of the $9.08 low (-29.5%).
CTVA is better suited for long-term investors with a 12-24 month horizon who can tolerate extreme volatility. The stock's beta is not provided, but the -86.83% max drawdown and 84% single-day gap imply realized volatility far above market levels, making it unsuitable for short-term trading unless using tight stops. The spin-off catalyst is a multi-quarter event, and the company's seasonal cash flow pattern means earnings visibility is low in the near term. A dividend yield of 1.04% provides minimal income support. We recommend a minimum holding period of 12 months to allow the spin-off to complete and the market to re-price the standalone entities. Short-term traders should wait for a confirmed base above $14.62 before entering.